Fa. Ebeid et al., TREATMENT OF EXPERIMENTAL SCHISTOSOMIASIS-MANSONI WITH PRAZIQUANTEL ALONE AND COMBINED WITH CIMETIDINE, Arzneimittel-Forschung, 44-2(11), 1994, pp. 1268-1270
In this work, praziquantel (EMBAY 8440, CAS 55268-74-1), an oral antih
elminthic drug effective against the three species of schistosomes pat
hogenic to man, was tested alone and in combination with cimetidine (C
AS 51481-61-9), aH(2)-receptor antagonist having a known potentiative
power when combined with other drugs. Both drugs were tested in differ
ent doses and regimen either alone or in combination by giving them to
S. mansoni infected Swiss albino mice (100 cercariae/mouse) 7 weeks p
ost infection. Cimetidine was tested in doses of 50, 100 and 200 mg/kg
for 2 consecutive days; praziquantel was given in doses of 100 and 50
0 mg/kg for 2 consecutive days reduced the total worm load by 84.61%,
while a percent reduction of 75.1% and 88.9% was recorded in hepatic a
nd intestinal tissue egg load, respectively. Maximum efficacy was reco
rded when both drugs were given simultaneously at 200 mg/kg for 2 cons
ecutive days. This regimen completely eradicated all schistosome worms
and resulted in the maximum reduction in total tissue egg load (92%).
The efficacy of this regimen was nearly the same as that of the full
dose of praziquantel (500 mg/kg for 2 consecutive days), gave 100% wor
m eradication and 95% reduction in total tissue egg load.